Risk Stratified Sequential Treatment for CD20-positive PTLD

PTLD Clinical Trial

— PTLD-1/3  

Official title:

Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (PTLD-1/3)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00590447
• Other study ID #: PTLD-1, 3rd. amendment
• Secondary ID: EudraCT 2005-000
• Status: Completed
• Phase: Phase 2
• First received: December 28, 2007
• Last updated: March 6, 2017
• Start date: December 2006
• Est. completion date: July 2015

Study information

• Verified date: March 2017
• Source: Charite University, Berlin, Germany
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase-II trial will investigate the efficacy, safety and the tolerability of a sequential therapy consisting of 4 courses of single agent rituximab followed by 4 courses of R-CHOP chemotherapy in patients with CD20+ posttransplant lymphoproliferative disorders (PTLD). However, responders to rituximab achieving a CR after the first 4 applications of rituximab will go on with rituximab monotherapy and will not receive chemotherapy.

Description:

The rationale for performing the present study is to combine two highly active treatment modalities in first line therapy of solid organ recipients with B-cell PTLD. The monoclonal antibody CD20 represents an effective therapeutic approach in the treatment of PTLD. Unfortunately this effect seems to be of limited duration in some patients, who benefited from monotherapy with rituximab. The advantage of this therapeutic approach in PTLD is due to the low incidence of third to fourth degree adverse events. At diagnosis of PTLD a relevant proportion of these patients is not suitable for first line cytotoxic chemotherapy due to widespread disease, organ dysfunction or reduced performance state. Insufficiencies of kidney or bone marrow function are frequent in organ recipients due the toxic side effects of the immunosuppressive drugs. After pre-phase treatment with the monoclonal antibody rituximab the CHOP chemotherapy is suggested to be less toxic due to the lower tumor burden. Thereby treatment related severe or even lethal toxicities, frequently reported in patients with PTLD who underwent cytotoxic chemotherapy, may be prevented. Furthermore the total number of cytotoxic cycles of CHOP-therapy is reduced from 6 for 8 to 4 cycles and thus may result in an additional reduction of toxicity in the single patient. Because immunochemotherapy (R-CHOP) is clearly superior to CHOP with respect to progression free survival and relapse rates in patients with classical NHL and rituximab is very unlikely to add any further toxicity to CHOP the majority of patients will go on with four courses of R-CHOP. However, patients with a complete remission after 4 courses of single agent rituximab may have a very favourable risk profile and therefore will go on with rituximab single agent instead of R-CHOP.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 152
• Est. completion date: July 2015
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• PTLD with or without EBV association, confirmed after biopsy or resection of tumor

• Measurable disease of > 2 cm in diameter and/or bone marrow involvement

• Patients having undergone heart, lung, liver, kidney, pancreas, small intestine transplantation or other or a combination of the organ transplantations mentioned

• Karnofsky scale >50% or ECOG = 3

• Reduction of immunosuppression with or without antiviral therapy

• A complete surgical extirpation of tumor was not performed

• A radiation therapy was not performed

• Effective contraception for women in childbearing age

• Patient's written informed consent and written consent for data collection

• Patients are > 18 years (or = 15 years with parental agreement )

Exclusion Criteria:

• Life expectancy less than 6 weeks

• Karnofsky-scale <50% or ECOG = 3

• Treatment with rituximab before

• Known allergic reactions against foreign proteins

• Concomitant diseases, which exclude the administration of therapy as outlined by the study protocol

• non-compensated heart failure

• Dilatative cardiomyopathy

• Myocardial infarction during the last 6 months

• Severe non-compensated hypertension

• Severe non-compensated diabetes mellitus

• Renal insufficiency (creatinine more than 3-fold of the upper normal value), not related to lymphoma

• Hepatic insufficiency with transaminase values greater than 3-fold of the normal values and/or bilirubin levels >3.0 mg/dl, not related to lymphoma

• Clinical signs of cerebral dysfunction

• Women during the lactation period, pregnant or of childbearing potential not using a reliable contraceptive method

• Involvement of the central nervous system by the disease

• Severe psychiatric disease

• Known to be HIV positive

• Missing written informed consent of the patient

Related Conditions & MeSH terms

• Lymphoproliferative Disorders
• Posttransplant Lymphoproliferative Disorder
• PTLD

Intervention

Drug:
• rituximab monotherapy
375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
• sequential R-CHOP
375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy.

Locations

Country	Name	City	State
Australia	Princess Alexandra Hospital, Ipswich Rd, Woolloongabba, Qld 4102	Brisbane
Belgium	Catholic University of Leuven, Department of Hematology	Leuven
France	Hôpital Pitié-Salpétrière, Department of Hematology, 47-83 Boulevard de l'Hopital	Paris
Germany	Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Hematology and Oncology, Augustenburger Platz 1	Berlin
Italy	Div. Universitaria Ematologia e Terapie Cellulari, University of Torino	Torino
Poland	Zaklad Propedeutyki Onkologii, Gdanskiego Uniwersytetu Medycznego	Gdynia
Sweden	Sahlgrens hospital, Department of Hematology	Göteborg

Sponsors (1)

Lead Sponsor	Collaborator
Charite University, Berlin, Germany

Countries where clinical trial is conducted

Australia,  Belgium,  France,  Germany,  Italy,  Poland,  Sweden, 

References & Publications (1)

Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary objective is the evaluation of the efficacy.For this aim the overall objective response rates after therapy = complete and partial response and the duration of the response will be measured.		evaluated 4 weeks after comleting therapy
Secondary	The secondary objective is to determine the adverse events and tolerability of rituximab and/or chemotherapy. Furthermore, the long-term safety will be determined, especially the frequency of complicating infections and the overall survival.		within 2 years of follow up

External Links

•   Protocol and CRF download